Who We Are
About Us


Our Mission


Our mission is to positively transform lives through the development of pioneering gene therapy treatments for Limb-Girdle Muscular Dystrophies (LGMDs).


Our Focus


We are developing five novel gene therapies licensed from Nationwide Children’s Hospital, a global leader in neuromuscular disease therapeutic discovery and translational research:

MYO-101: LGMD2E (β-sarcoglycanopathy)

The goal of gene therapy for LGMD2E is long-term expression of β-sarcoglycan after administration of a vector carrying the SCGB gene. Increased levels of β-sarcoglycan are expected to produce improvement in symptoms related to the disease.

MYO-102: LGMD2D (α-sarcoglycanopathy)

The goal of gene therapy for LGMD2D is long-term expression of α-sarcoglycan after administration of a vector carrying the SCGA gene. Increased levels of α-sarcoglycan are expected to produce improvement in symptoms related to the disease.

MYO-103: LGMD2C (γ-sarcoglycanopathy)

The goal of gene therapy for LGMD2C is long-term expression of γ-sarcoglycan after administration of a vector carrying the SCGG gene. Increased levels of γ-sarcoglycan are expected to produce improvement in symptoms related to the disease.

MYO-201: LGMD2B (Dysferlinopathy or Miyoshi Myopathy)

The goal of gene therapy for LGMD2B is long-term expression of dysferlin after administration of a vector carrying the DYSF gene. Increased levels of dysferlin are expected to produce improvement in symptoms related to the disease.

MYO-301: LGMD2L (Anoctaminopathy)

The goal of gene therapy for LGMD2L is long-term expression of anoctamin-5 after administration of a vector carrying the ANO5 gene. Increased levels of anoctamin-5 are expected to produce improvement in symptoms related to the disease.

Our Management


An innovative, strategically focused management team with neuromuscular disease gene therapy, global drug development, and new venture development expertise.

Mike Triplett

Michael Triplett, Ph.D.

President & Chief Executive Officer
Bruce Halpryn

Bruce Halpryn, Ph.D.

Secretary & Chief Operating Officer
Louise Rodino-Klapac

Louise Rodino-Klapac, Ph.D.

Chief Scientific Officer

Peter Kleinhenz, MBA

Treasurer & Chief Financial Officer

Michael Triplett, Ph.D.

President & CEO, Myonexus Therapeutics, Inc.

Bruce Halpryn, Ph.D.

Secretary & COO, Myonexus Therapeutics, Inc.

Bryan Barber

President and Founder of the LGMD2D Foundation
President and co-founder of ADVANTIS Global Inc.

John Rice, Ph.D.

Chairman, Board of Directors, Myonexus Therapeutics, Inc.
Director, Life Sciences CincyTech LLC

Robert Beech

Executive Chairman & Co-founder, Eccrine Systems, Inc.

Dione Kobayashi, Ph.D.

VP, Preclinical Translation, Cydan

Jerry Mendell, MD

Principal Investigator, Center for Gene Therapy & Director, Neuromuscular Disorders, Nationwide Children’s Hospital

Laura Rufibach, Ph.D.

Co-President, Jain Foundation

Yvan Torrente, Ph.D.

MD, Assistant Professor in Neurology, University of Milan

Matthew Wicklund, MD

Professor and Director, Clinical Neuromuscular Pathology, University of Colorado School of Medicine

Bryan Barber (Chair)

Co-Founder, Myonexus Therapeutics and Founder & President, LGMD2D Foundation

Scott Frewing

Co-Founder & President, Kurt+Peter Foundation

Kristin Stephenson

VP of Policy & Advocacy, Muscular Dystrophy Association

Josh Thayer, JD

General Counsel, Jain Foundation

Beatrice Vola

President, GFB Onlus

Brad Williams, PhD

Director of Research and Advanced Diagnostics, Jain Foundation